Atherotech Adds New Cardiometabolic Tests For AMI, Stroke, Kidney Disease

 

August 13, 2009

August, 13, 2009 – Atherotech Inc. this week added two new cardiometabolic tests – the PLAC Test for identification of increased heart attack and stroke risk, and the Cystatin C test as an early, sensitive marker for chronic kidney disease.

The tests expand Atherotech's cardiovascular disease and metabolic panels and complement the company's advanced lipid profile, the VAP (Vertical Auto Profile) Test.

Cardiometabolic and genetic tests already available from Atherotech include C-Reactive Protein (hsCRP), apoE genotype, NT-proBNP, homocysteine, creatinine, creatine kinase (CK), HbA1c, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D and insulin. Cardiometabolic test panels can be ordered individually or bundled as part of a custom risk profile that also includes the VAP expanded cholesterol profile.

The VAP Cholesterol Test provides physician practices, researchers and healthcare providers with direct measurement of LDL, HDL and all relevant subclasses, and includes nonHDL, apoB, and emerging risk factors such as Lp(a), remnants and small dense LDL. The VAP Test is the only single cholesterol test that routinely reports apoAI, apoB and the apoB/apoAI ratio.

For more information: www.thevaptest.com